Transcriptomics Market by Product & Services, Technology, Application, and End User

Description

List of Tables

Transcriptomics Market by Product & Services, Technology (Next-Generation Sequencing, PCR-based Technologies), Application (Drug Discovery & Development, Clinical Diagnostic), End User, and Geography - Forecast to 2035

According to the research report titled, 'Transcriptomics Market by Product & Services (Consumables, Instruments, Software & Services), Technology (Next-Generation Sequencing, PCR-based Technologies), Application (Drug Discovery & Development, Clinical Diagnostic), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), and Geography - Global Forecast to 2035,' the transcriptomics market is projected to reach $15.32 billion by 2035, at a CAGR of 6.3% during the forecast period 2025-2035. The report provides an in-depth analysis of the global transcriptomics market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2035.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by rapid advancements in next-generation sequencing (NGS) technologies, growing demand for personalized medicine, increasing prevalence of cancer and chronic diseases, expanding applications in drug discovery and development, and declining sequencing costs. Moreover, integration of single-cell and spatial transcriptomics workflows, rise of multi-omics approaches, implementation of artificial intelligence and machine learning in data analysis, expansion of clinical transcriptomics for diagnostics, and growing government funding for genomics research are expected to support the market's growth.

The key players operating in the transcriptomics market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), 10x Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Ltd. (U.K.), Pacific Biosciences of California, Inc. (U.S.), Merck KGaA (Germany), Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), Fluidigm Corporation (U.S.), and Promega Corporation (U.S.).

The transcriptomics market is segmented by product & services (consumables, instruments, and software & services), technology (next-generation sequencing, microarrays, PCR-based technologies, and other technologies), application (drug discovery & development, clinical diagnostics, personalized medicine, agricultural & animal research, and other applications), end user (pharmaceutical & biotechnology companies, academic & research institutes, clinical diagnostic laboratories, contract research organizations, and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Market Analysis by Segments

Based on Product & Services

The consumables segment is projected to account for the largest market share of approximately 51% in 2025. The dominance of this segment is primarily attributed to the recurring and high-volume nature of consumable usage across RNA-based workflows, continuous consumption of reagents for every sample processed, advancements in library preparation chemistries and automation-compatible reagent kits, and growing adoption of specialized consumables for low-input and single-cell samples. Transcriptomic studies require ongoing consumption of RNA extraction kits, library preparation kits, sequencing reagents, and PCR consumables, making this a key revenue driver for vendors.

However, the consumables segment is also expected to register the highest CAGR of 7.2% during the forecast period, driven by rising adoption of NGS-based RNA-seq and single-cell transcriptomics, expansion of sequencing service providers and decentralized testing, increasing throughput requirements across research and clinical settings, and development of innovative reagent formulations for emerging applications.

Based on Technology

The next-generation sequencing segment is expected to dominate the transcriptomics market in 2025, accounting for approximately 71% market share. This segment's leadership is primarily driven by comprehensive transcriptome coverage provided by NGS technologies, continuous decline in sequencing costs making NGS accessible to more laboratories, superior ability to detect novel transcripts and splice variants compared to other technologies, growing adoption of single-cell and spatial transcriptomics applications exclusively enabled by sequencing approaches, and preference for hypothesis-free discovery approaches. NGS enables unbiased transcriptome-wide analysis, providing insights into gene expression, alternative splicing, and transcript isoforms that are not possible with targeted methods.

The next-generation sequencing segment is also projected to register the highest CAGR of 7.3% during the forecast period, attributed to ongoing technological innovations improving sequencing accuracy and throughput, expanding applications in precision medicine and clinical diagnostics, increasing investments in genomics infrastructure by pharmaceutical and biotechnology companies, development of long-read sequencing technologies for comprehensive transcript characterization, and growing preference for comprehensive molecular profiling in research and clinical settings.

Based on Application

The drug discovery & development segment is expected to account for the largest share of approximately 35% of the transcriptomics market in 2025. This leadership is attributed to extensive use of transcriptomics throughout pharmaceutical development pipelines, growing investments in biologics and precision medicine requiring molecular characterization, increasing adoption of target-based drug discovery approaches, expanding applications in biomarker discovery for patient stratification, and utility in understanding mechanism of action and safety profiling. Pharmaceutical companies leverage transcriptomics to identify therapeutic targets, evaluate drug efficacy, understand treatment resistance mechanisms, and guide clinical trial design.

However, the personalized medicine segment is projected to register the highest CAGR of 8.0% during the forecast period, driven by increasing need for precise, patient-specific insights beyond traditional genetic testing, real-time measurement of gene expression for understanding disease pathways and drug response, rapid adoption of RNA-based biomarkers in oncology, immunology, and rare diseases, integration of precision medicine programs in healthcare systems, and growing requirement for transcriptomic profiling in guiding targeted therapies and monitoring therapeutic efficacy.

Based on End User

The pharmaceutical & biotechnology companies segment is expected to account for the largest share of approximately 40% of the transcriptomics market in 2025. This dominance is primarily driven by extensive use of transcriptomics throughout drug discovery and development pipelines, growing investments in precision medicine initiatives requiring molecular profiling, increasing adoption of transcriptomics in clinical trials for patient stratification, ongoing development of RNA-based therapeutics necessitating comprehensive transcriptomic characterization, and establishment of in-house sequencing capabilities for high-throughput analysis. These companies utilize transcriptomics for target identification, lead optimization, biomarker discovery, and companion diagnostics development.

Along with pharmaceutical & biotechnology companies, the contract research organizations (CROs) segment is also expected to register the highest CAGR of 7.1% during the forecast period. This rapid growth is driven by increasing outsourcing of RNA-seq, single-cell sequencing, and spatial transcriptomics services, complexity and high cost of advanced transcriptomic workflows making outsourcing attractive, CROs offering end-to-end solutions from sample preparation to bioinformatics interpretation, growing demand for specialized expertise and scalable infrastructure, and expansion of service portfolios to include cutting-edge technologies and AI-powered analytics.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region.

North America is expected to account for the largest share of approximately 40% of the global transcriptomics market in 2025. This dominance is attributed to strong presence of leading biotechnology and pharmaceutical companies, well-established genomics research infrastructure, high adoption of advanced sequencing technologies, substantial government and private funding for genomics research through the National Institutes of Health and other organizations, and early adoption of transcriptomic diagnostics in clinical practice. The region benefits from comprehensive healthcare systems, major research institutions, and significant investments in precision medicine initiatives.

However, Asia-Pacific is projected to register the highest CAGR during the forecast period across the overall transcriptomics market. This growth is fueled by increasing investments in genomics research infrastructure, growing pharmaceutical and biotechnology sectors in countries like China and India, rising healthcare expenditure and improving access to advanced diagnostics, expanding academic research collaborations with Western institutions, government initiatives supporting precision medicine and genomics programs, and large-scale population genomics projects. Countries such as China have made substantial investments in genomics capabilities and launched national genomics programs. The region's growing middle-class population, improving healthcare infrastructure, increasing focus on personalized medicine, and supportive regulatory frameworks for genomics research are creating a conducive environment for market expansion. Additionally, the region's expanding clinical research activities, growing contract research organizations, and increasing pharmaceutical R&D investments contribute to higher adoption of transcriptomic technologies.

Key Questions Answered in the Report

What is the current revenue generated by the transcriptomics market globally?
At what rate is the global transcriptomics demand projected to grow for the next 7-10 years?
What are the historical market sizes and growth rates of the global transcriptomics market?
What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
Which segments in terms of product & services, technology, application, and end user are expected to create major traction for the manufacturers in this market?
What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global transcriptomics market?
Who are the major players in the global transcriptomics market? What are their specific product offerings in this market?
What are the recent strategic developments in the global transcriptomics market? What are the impacts of these strategic developments on the market?

Scope of the Report

Transcriptomics Market Assessment - by Product & Services

Consumables
Instruments
Software & Services

Transcriptomics Market Assessment - by Technology

Next-Generation Sequencing (NGS)
Microarrays
PCR-based Technologies
Other Technologies

Transcriptomics Market Assessment - by Application

Drug Discovery & Development
Clinical Diagnostics
Personalized Medicine
Agricultural & Animal Research
Other Applications

Transcriptomics Market Assessment - by End User

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Clinical Diagnostic Laboratories
Contract Research Organizations (CROs)
Other End Users

Transcriptomics Market Assessment - by Geography

North America

U.S.
Canada

Europe

Germany
France
U.K.
Italy
Spain
Rest of Europe

Asia-Pacific

China
India
Japan
South Korea
Australia & New Zealand
Rest of Asia-Pacific

Latin America

Brazil
Mexico
Argentina
Rest of Latin America

Middle East & Africa

Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa

Product Code: MRHC - 1041636

1 Introduction

1.1. Market Definition & Scope
1.2. Currency & Limitations

2 Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study

3 Executive Summary

4 Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
  - 4.2.1.1. Increasing Demand for Personalized Medicine is Driving Market Growth
  - 4.2.1.2. Rising Prevalence of Cancer and Chronic Diseases is Propelling the Market
  - 4.2.1.3. Advancements in Next-Generation Sequencing Technologies Are Accelerating Market Expansion
  - 4.2.1.4. Growing Applications in Drug Discovery and Development
  - 4.2.1.5. Increasing Government Funding and Investments in Genomics Research
- 4.2.2. Restraints
  - 4.2.2.1. High Cost of Transcriptomic Instruments and Services is Restraining Market Growth
  - 4.2.2.2. Lack of Skilled Professionals for Data Analysis and Interpretation
  - 4.2.2.3. Stringent Regulatory Requirements for Clinical Applications
- 4.2.3. Opportunities
  - 4.2.3.1. Emerging Applications in Spatial Transcriptomics Offer Significant Growth Opportunities
  - 4.2.3.2. Integration of Artificial Intelligence and Machine Learning in Data Analysis
  - 4.2.3.3. Expanding Applications in Agricultural and Environmental Research
  - 4.2.3.4. Growing Adoption in Emerging Markets
- 4.2.4. Challenges
  - 4.2.4.1. Data Storage and Management Challenges
  - 4.2.4.2. Lack of Standardization in Transcriptomic Workflows
- 4.2.5. Trends
  - 4.2.5.1. Single-Cell Transcriptomics is Revolutionizing Biological Research
  - 4.2.5.2. Long-Read Sequencing Technologies Are Enhancing Transcriptome Characterization
4.3. Regulatory Analysis
- 4.3.1. International Organization for Standardization (Iso)
- 4.3.2. North America
  - 4.3.2.1. U.S.
  - 4.3.2.2. Canada
- 4.3.3. Europe
- 4.3.4. Asia-Pacific
  - 4.3.4.1. China
  - 4.3.4.2. Japan
  - 4.3.4.3. India
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa
4.4. Value Chain Analysis
- 4.4.1. Raw Material Suppliers
- 4.4.2. Component Manufacturers
- 4.4.3. Product Manufacturers
- 4.4.4. Distributors and Service Providers
- 4.4.5. End Users
- 4.4.6. Value Addition at Each Stage

5 Global Transcriptomics Market Assessment - By Product & Service

5.1. Overview
5.2. Consumables
- 5.2.1. RNA Extraction & Purification Kits
- 5.2.2. Library Preparation Kits
- 5.2.3. Sequencing Reagents & Kits
- 5.2.4. PCR Reagents & Kits
- 5.2.5. Other Consumables
5.3. Instruments
- 5.3.1. Sequencers
  - 5.3.1.1. Next-Generation Sequencers
    - 5.3.1.1.1. Third-Generation Sequencers
    - 5.3.1.1.2. Sanger Sequencers
- 5.3.2. PCR Instruments
  - 5.3.2.1. Real-Time PCR Systems
  - 5.3.2.2. Digital PCR Systems
  - 5.3.2.3. Standard PCR Systems
- 5.3.3. Other Instruments
5.4. Software and Services
- 5.4.1. Bioinformatics Software
  - 5.4.1.1. Data Analysis Software
  - 5.4.1.2. Data Management Software
- 5.4.2. Sequencing Services
- 5.4.3. Data Analysis Services
- 5.4.4. Other Services

6 Global Transcriptomics Market Assessment - By Technology

6.1. Overview
6.2. Next-Generation Sequencing (NGS)
- 6.2.1. RNA-Seq
- 6.2.2. Single-Cell RNA-Seq
- 6.2.3. Spatial Transcriptomics
- 6.2.4. Long-Read RNA Sequencing
- 6.2.5. Small RNA Sequencing
6.3. PCR-based Technologies
- 6.3.1. qRT-PCR
- 6.3.2. Digital PCR
- 6.3.3. Other PCR Expression Assays
6.4. Other Technologies

7 Global Transcriptomics Market Assessment - By Application

7.1. Overview
7.2. Drug Discovery & Development
- 7.2.1. Target Identification & Validation
- 7.2.2. Biomarker Discovery
- 7.2.3. Toxicology Studies
- 7.2.4. Lead Optimization
7.3. Clinical Diagnostics
- 7.3.1. Oncology Diagnostics
- 7.3.2. Infectious Disease Diagnostics
- 7.3.3. Genetic Disorder Diagnostics
- 7.3.4. Other Clinical Diagnostics
7.4. Personalized Medicine
7.5. Agricultural & Animal Research
7.6. Other Applications

8 Global Transcriptomics Market Assessment - By End User

8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Academic & Research Institutes
8.4. Clinical Diagnostic Laboratories
8.5. Contract Research Organizations (Cros)
8.6. Other End Users

9 Transcriptomics Market Assessment, By Geography

9.1. Overview
9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
9.3. Europe
- 9.3.1. Germany
- 9.3.2. U.K.
- 9.3.3. Italy
- 9.3.4. Spain
- 9.3.5. Switzerland
- 9.3.6. Belgium
- 9.3.7. Rest of Europe
9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. Australia
- 9.4.5. Rest of Asia-Pacific
9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
9.6. Middle East & Africa
- 9.6.1. UAE
- 9.6.2. Saudi Arabia
- 9.6.3. South Africa
- 9.6.4. Rest of Middle East & Africa

10 Competitive Landscape

10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.4.4. Emerging Companies
10.5. Market Share/Position Analysis

11 Company Profiles

11.1. Illumina, Inc. (U.S.)
- 11.1.1. Company Overview
- 11.1.2. Financial Overview
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Developments
11.2. Thermo Fisher Scientific, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Overview
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Developments
11.3. Agilent Technologies, Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Overview
- 11.3.3. Product Portfolio
11.4. Qiagen N.V.
- 11.4.1. Company Overview
- 11.4.2. Financial Overview
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Developments
11.5. Bio-Rad Laboratories, Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Overview
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Developments
11.6. F. Hoffmann-La Roche Ltd. (U.S.)
- 11.6.1. Company Overview
- 11.6.2. Financial Overview
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Developments
11.7. 10x Genomics, Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Overview
- 11.7.3. Product Portfolio
11.8. Takara Bio Inc. (U.S.)
- 11.8.1. Company Overview
- 11.8.2. Product Portfolio
- 11.8.3. Strategic Developments
11.9. Oxford Nanopore Technologies Ltd.
- 11.9.1. Company Overview
- 11.9.2. Product Portfolio
- 11.9.3. Strategic Developments
11.10. Pacific Biosciences of California, Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Overview
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Developments
11.11. Merck Kgaa
- 11.11.1. Company Overview
- 11.11.2. Financial Overview
- 11.11.3. Product Portfolio
- 11.11.4. Swot Analysis
11.12. Bruker Corporation (U.S.)
- 11.12.1. Company Overview
- 11.12.2. Financial Overview
- 11.12.3. Product Portfolio
- 11.12.4. Strategic Developments
11.13. Perkinelmer, Inc. (U.S.)
- 11.13.1. Company Overview
- 11.13.2. Product Portfolio
11.14. Fluidigm Corporation (Standard Biotools Inc.)
- 11.14.1. Company Overview
- 11.14.2. Financial Overview
- 11.14.3. Product Portfolio
11.15. Promega Corporation
- 11.15.1. Company Overview
- 11.15.2. Product Portfolio
- 11.15.3. Strategic Developments

12 Appendix

12.1. Available Customization
12.2. Related Reports